Butterfly Skin Therapy Pipeline Primed For Transformation

As Amryt's Oleogel-S10 Gets Priority Review

No drugs are approved for epidermolysis bullosa and children with so-called butterfly skin are currently treated by cleaning open wounds and bandaging them. This could soon change.

butterfly
• Source: Archive

The odds of having an approved therapy for epidermolysis bullosa (EB) by the end of 2021 have improved with the news that US regulators have fast-tracked Amryt Pharma's Oleogel-S10 but gene therapies are also coming through the pipeline that could tackle the underlying cause of the rare genetic disorder that causes skin to be extremely fragile.

First up, Ireland's Amryt, which is listed on the NASDAQ and London's AIM market, has revealed that the US Food...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist boosts its sales force ahead of the launch of Anzupgo.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

More from Therapy Areas

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.